Actions of prostacyclin (PGI2) and its product, 6-oxo-PGF1alpha on the rat gastric mucosa in vivo and in vitro.
The effects of prostacyclin (PGI2) and its breakdown product 6-oxo-PGF1alpha on various aspects of gastric function were investigated in the rat. PGI2 increased mucosal blood flow when infused intravenously. PGI2 was a more potent inhibitor of gastric acid secretion in vivo than PGE2. Like PGE2, PGI2 inhibited acid secretion from the rat stomach in vitro. PGI2 had comparable activity to PGE2 in inhibiting indomethacin-induced gastric erosions. Thus prostacyclin shares several of the activities of PGE2, and may be involved in the regulation of gastric mucosal function.
D000818:Animals; D011464:Epoprostenol / Q000008:administration & dosage / Q000494:pharmacology*; D005750:Gastric Juice / Q000378:metabolism*; D005753:Gastric Mucosa / Q000098:blood supply / Q000187:drug effects*; D007213:Indomethacin / Q000037:antagonists & inhibitors; D007263:Infusions, Parenteral; D010418:Pentagastrin / Q000494:pharmacology; D011453:Prostaglandins / Q000494:pharmacology*; D011458:Prostaglandins E / Q000494:pharmacology; D011461:Prostaglandins F, Synthetic / Q000494:pharmacology*; D051381:Rats; D012636:Secretory Rate / Q000187:drug effects; D013272:Stomach Diseases / Q000139:chemically induced
D011453:Prostaglandins; D011458:Prostaglandins E; D011461:Prostaglandins F, Synthetic; D011464:Epoprostenol; D010418:Pentagastrin; D007213:Indomethacin